XLO
Xilio Therapeutics, Inc.
Price Chart
Latest Quote
$0.59
Current Price| Previous Close | $0.59 |
| Open | $0.60 |
| Day High | $0.60 |
| Day Low | $0.54 |
| Volume | 913,396 |
Stock Information
| Shares Outstanding | 67.54M |
| Total Debt | $7.26M |
| Cash Equivalents | $103.76M |
| Revenue | $31.80M |
| Net Income | $-58.49M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $39.69M |
| EPS (TTM) | $-0.61 |
| Exchange | NCM |
đ Custom Metrics & Score
Score: 13/42| Debt to Equity | 0.46 |
| Debt to Earnings | -0.14 |
| Current Ratio | 2.21 |
| Quick Ratio | 2.03 |
| Profit Margin | -918.05% |
| Return on Equity | -330.95% |
| Avg FCF Growth | -19.38% |
| FCF Yield | -46.40% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $0.59 | 915,322 |
| 2026-01-30 | $0.60 | 524,200 |
| 2026-01-29 | $0.61 | 458,000 |
| 2026-01-28 | $0.62 | 342,200 |
| 2026-01-27 | $0.62 | 130,000 |
| 2026-01-26 | $0.63 | 164,700 |
| 2026-01-23 | $0.63 | 718,400 |
| 2026-01-22 | $0.62 | 1,714,400 |
| 2026-01-21 | $0.60 | 600,100 |
| 2026-01-20 | $0.63 | 433,500 |
| 2026-01-16 | $0.64 | 132,900 |
| 2026-01-15 | $0.64 | 521,100 |
| 2026-01-14 | $0.65 | 224,900 |
| 2026-01-13 | $0.66 | 220,000 |
| 2026-01-12 | $0.67 | 157,500 |
| 2026-01-09 | $0.68 | 564,800 |
| 2026-01-08 | $0.72 | 323,300 |
| 2026-01-07 | $0.70 | 383,000 |
| 2026-01-06 | $0.69 | 618,100 |
| 2026-01-05 | $0.68 | 209,400 |
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
đ° Latest News
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates
Zacks âĸ 2025-11-12T13:25:01Z
Xilio Therapeutics Second Quarter 2025 Earnings: US$0.16 loss per share (vs US$0.32 loss in 2Q 2024)
Simply Wall St. âĸ 2025-08-16T13:54:14Z
Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates
Zacks âĸ 2025-08-14T12:35:02Z
Snap downgraded, Leidos upgraded: Wall Street's top analyst calls
The Fly âĸ 2025-08-06T13:36:40Z
Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates
Zacks âĸ 2025-03-11T12:45:04Z
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
Zacks âĸ 2025-02-14T13:03:00Z
AbbVie and Xilio to collaborate on antibody-based immunotherapies
Pharmaceutical Technology âĸ 2025-02-13T09:17:48Z
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?
Benzinga âĸ 2025-02-12T15:44:46Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $6,344,000 | $0 | $0 | $0 |
| Operating Revenue | $6,344,000 | $0 | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $65,989,000 | $79,133,000 | $89,149,000 | $75,044,000 |
| Other Income Expense | $1,404,000 | $2,729,000 | $927,000 | $-756,000 |
| Other Non Operating Income Expenses | $2,341,000 | $2,729,000 | $927,000 | $-756,000 |
| Operating Expense | $65,989,000 | $79,133,000 | $89,149,000 | $75,044,000 |
| General And Administrative Expense | $24,778,000 | $26,997,000 | $29,948,000 | $23,856,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-58,241,000 | $-76,404,000 | $-88,222,000 | $-75,800,000 |
| Normalized Income | $-57,304,000 | $-76,404,000 | $-88,222,000 | $-75,800,000 |
| Net Income From Continuing And Discontinued Operation | $-58,241,000 | $-76,404,000 | $-88,222,000 | $-75,800,000 |
| Total Operating Income As Reported | $-60,582,000 | $-79,133,000 | $-89,149,000 | $-75,044,000 |
| Net Income Common Stockholders | $-58,241,000 | $-76,404,000 | $-88,222,000 | $-75,800,000 |
| Net Income | $-58,241,000 | $-76,404,000 | $-88,222,000 | $-75,800,000 |
| Net Income Including Noncontrolling Interests | $-58,241,000 | $-76,404,000 | $-88,222,000 | $-75,800,000 |
| Net Income Continuous Operations | $-58,241,000 | $-76,404,000 | $-88,222,000 | $-75,800,000 |
| Pretax Income | $-58,241,000 | $-76,404,000 | $-88,222,000 | $-75,800,000 |
| Special Income Charges | $-937,000 | $0 | - | - |
| Operating Income | $-59,645,000 | $-79,133,000 | $-89,149,000 | $-75,044,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-1.09 | $-2.78 | $-3.22 | $-13.52 |
| Basic EPS | $-1.09 | $-2.78 | $-3.22 | $-13.52 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-57,064,000 | $-77,233,000 | $-87,302,000 | $-73,545,000 |
| Total Unusual Items | $-937,000 | $0 | - | - |
| Total Unusual Items Excluding Goodwill | $-937,000 | $0 | - | - |
| Reconciled Depreciation | $1,644,000 | $1,900,000 | $1,847,000 | $1,499,000 |
| EBITDA (Bullshit earnings) | $-58,001,000 | $-77,233,000 | $-87,302,000 | $-73,545,000 |
| EBIT | $-59,645,000 | $-79,133,000 | $-89,149,000 | $-75,044,000 |
| Diluted Average Shares | $53,511,424 | $27,496,107 | $27,392,087 | $5,606,308 |
| Basic Average Shares | $53,511,424 | $27,496,107 | $27,392,087 | $5,606,308 |
| Diluted NI Availto Com Stockholders | $-58,241,000 | $-76,404,000 | $-88,222,000 | $-75,800,000 |
| Restructuring And Mergern Acquisition | $937,000 | $0 | - | - |
| Research And Development | $41,211,000 | $52,136,000 | $59,201,000 | $51,188,000 |
| Selling General And Administration | $24,778,000 | $26,997,000 | $29,948,000 | $23,856,000 |
| Other Gand A | $10,132,000 | $11,170,000 | $13,247,000 | $11,148,000 |
| Salaries And Wages | $14,646,000 | $15,827,000 | $16,701,000 | $12,708,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $17,598,000 | $36,827,000 | $105,647,000 | $185,429,000 |
| Total Assets | $71,075,000 | $60,926,000 | $139,165,000 | $218,060,000 |
| Total Non Current Assets | $10,841,000 | $12,799,000 | $14,669,000 | $15,543,000 |
| Other Non Current Assets | $1,782,000 | $1,732,000 | $1,829,000 | $1,946,000 |
| Current Assets | $60,234,000 | $48,127,000 | $124,496,000 | $202,517,000 |
| Other Current Assets | $4,943,000 | $3,423,000 | $4,111,000 | $4,464,000 |
| Cash Cash Equivalents And Short Term Investments | $55,291,000 | $44,704,000 | $120,385,000 | $198,053,000 |
| Cash And Cash Equivalents | $55,291,000 | $44,704,000 | $120,385,000 | $198,053,000 |
| Prepaid Assets | - | - | $4,111,000 | $4,464,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $8,142,000 | $12,504,000 | $19,939,000 | $20,536,000 |
| Long Term Debt And Capital Lease Obligation | $6,954,000 | $8,142,000 | $12,354,000 | $19,735,000 |
| Current Debt And Capital Lease Obligation | $1,188,000 | $4,362,000 | $7,585,000 | $801,000 |
| Current Debt | - | $3,315,000 | $6,667,000 | - |
| Other Current Borrowings | - | $3,315,000 | $6,667,000 | - |
| Long Term Debt | - | - | $3,165,000 | $9,628,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $53,477,000 | $24,099,000 | $33,518,000 | $32,631,000 |
| Total Non Current Liabilities Net Minority Interest | $26,216,000 | $8,142,000 | $12,399,000 | $19,853,000 |
| Non Current Deferred Liabilities | $19,262,000 | $0 | - | - |
| Current Liabilities | $27,261,000 | $15,957,000 | $21,119,000 | $12,778,000 |
| Current Deferred Liabilities | $13,518,000 | $0 | - | - |
| Payables And Accrued Expenses | $8,347,000 | $6,857,000 | $8,039,000 | $6,750,000 |
| Payables | $2,574,000 | $1,050,000 | $3,125,000 | $3,144,000 |
| Accounts Payable | $2,574,000 | $1,050,000 | $3,125,000 | $3,144,000 |
| Other Current Liabilities | - | $48,000 | $82,000 | $82,000 |
| Other Non Current Liabilities | - | - | $45,000 | $118,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $17,598,000 | $36,827,000 | $105,647,000 | $185,429,000 |
| Total Equity Gross Minority Interest | $17,598,000 | $36,827,000 | $105,647,000 | $185,429,000 |
| Stockholders Equity | $17,598,000 | $36,827,000 | $105,647,000 | $185,429,000 |
| Retained Earnings | $-383,753,000 | $-325,512,000 | $-249,108,000 | $-160,886,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $45,756,773 | $27,607,646 | $27,425,447 | $27,358,375 |
| Share Issued | $45,756,773 | $27,607,646 | $27,425,447 | $27,358,375 |
| Tangible Book Value | $17,598,000 | $36,827,000 | $105,647,000 | $185,429,000 |
| Invested Capital | $17,598,000 | $40,142,000 | $115,479,000 | $195,057,000 |
| Working Capital | $32,973,000 | $32,170,000 | $103,377,000 | $189,739,000 |
| Capital Lease Obligations | $8,142,000 | $9,189,000 | $10,107,000 | $10,908,000 |
| Total Capitalization | $17,598,000 | $36,827,000 | $108,812,000 | $195,057,000 |
| Additional Paid In Capital | $401,346,000 | $362,336,000 | $354,752,000 | $346,312,000 |
| Capital Stock | $5,000 | $3,000 | $3,000 | $3,000 |
| Common Stock | $5,000 | $3,000 | $3,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $19,262,000 | $0 | - | - |
| Long Term Capital Lease Obligation | $6,954,000 | $8,142,000 | $9,189,000 | $10,107,000 |
| Current Deferred Revenue | $13,518,000 | $0 | - | - |
| Current Capital Lease Obligation | $1,188,000 | $1,047,000 | $918,000 | $801,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,208,000 | $4,690,000 | $5,413,000 | $5,145,000 |
| Current Accrued Expenses | $5,773,000 | $5,807,000 | $4,914,000 | $3,606,000 |
| Net PPE | $9,059,000 | $11,067,000 | $12,840,000 | $13,597,000 |
| Accumulated Depreciation | $-7,427,000 | $-5,861,000 | $-4,418,000 | $-2,712,000 |
| Gross PPE | $16,486,000 | $16,928,000 | $17,258,000 | $16,309,000 |
| Leases | $5,124,000 | $5,124,000 | $5,124,000 | $5,124,000 |
| Other Properties | $10,498,000 | $10,940,000 | $11,172,000 | $9,782,000 |
| Machinery Furniture Equipment | $864,000 | $864,000 | $864,000 | $864,000 |
| Buildings And Improvements | $4,587,000 | $5,125,000 | - | - |
| Properties | $0 | $0 | $0 | $0 |
| Construction In Progress | - | $0 | $98,000 | $539,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-18,414,000 | $-69,106,000 | $-77,590,000 | $-81,851,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-18,378,000 | $-68,620,000 | $-75,723,000 | $-80,751,000 |
| Cash Flow From Continuing Operating Activities | $-18,378,000 | $-68,620,000 | $-75,723,000 | $-80,751,000 |
| Operating Gains Losses | $3,000 | $3,000 | $1,000 | $222,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-36,000 | $-486,000 | $-1,867,000 | $-1,100,000 |
| Investing Cash Flow | $-36,000 | $-486,000 | $-1,867,000 | $-1,100,000 |
| Cash Flow From Continuing Investing Activities | $-36,000 | $-486,000 | $-1,867,000 | $-1,100,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $6,825,000 | $0 | $0 | $261,245,000 |
| Financing Cash Flow | $29,196,000 | $-6,550,000 | $-69,000 | $260,668,000 |
| Cash Flow From Continuing Financing Activities | $29,196,000 | $-6,550,000 | $-69,000 | $260,668,000 |
| Net Common Stock Issuance | $6,825,000 | $0 | $0 | $116,359,000 |
| Common Stock Issuance | $6,825,000 | $0 | $0 | $116,359,000 |
| Net Preferred Stock Issuance | - | - | $0 | $144,886,000 |
| Preferred Stock Issuance | - | - | $0 | $144,886,000 |
| Net Other Financing Charges | - | - | - | $-750,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-3,382,000 | $-6,752,000 | $-85,000 | $-1,085,000 |
| Interest Paid Supplemental Data | $62,000 | $573,000 | $555,000 | $492,000 |
| End Cash Position | $57,073,000 | $46,291,000 | $121,947,000 | $199,606,000 |
| Beginning Cash Position | $46,291,000 | $121,947,000 | $199,606,000 | $20,789,000 |
| Changes In Cash | $10,782,000 | $-75,656,000 | $-77,659,000 | $178,817,000 |
| Proceeds From Stock Option Exercised | $25,753,000 | $202,000 | $16,000 | $283,000 |
| Net Issuance Payments Of Debt | $-3,382,000 | $-6,752,000 | $-85,000 | $-110,000 |
| Net Long Term Debt Issuance | $-3,382,000 | $-6,752,000 | $-85,000 | $-110,000 |
| Long Term Debt Payments | $-3,382,000 | $-6,752,000 | $-85,000 | $-1,085,000 |
| Net PPE Purchase And Sale | $-36,000 | $-486,000 | $-1,867,000 | $-1,100,000 |
| Purchase Of PPE | $-36,000 | $-486,000 | $-1,867,000 | $-1,100,000 |
| Change In Working Capital | $31,782,000 | $-1,658,000 | $2,004,000 | $-11,803,000 |
| Change In Other Working Capital | $32,780,000 | - | - | - |
| Change In Other Current Liabilities | $-1,047,000 | $-918,000 | $-801,000 | $-564,000 |
| Change In Other Current Assets | $539,000 | $460,000 | $391,000 | $332,000 |
| Change In Payables And Accrued Expense | $1,030,000 | $-1,888,000 | $2,070,000 | $-8,435,000 |
| Change In Accrued Expense | $-496,000 | $175,000 | $1,585,000 | $-5,617,000 |
| Change In Payable | $1,526,000 | $-2,063,000 | $485,000 | $-2,818,000 |
| Change In Account Payable | $1,526,000 | $-2,063,000 | $485,000 | $-2,818,000 |
| Change In Prepaid Assets | $-1,520,000 | $688,000 | $344,000 | $-3,136,000 |
| Stock Based Compensation | $6,434,000 | $7,382,000 | $8,424,000 | $4,958,000 |
| Depreciation Amortization Depletion | $1,644,000 | $1,900,000 | $1,847,000 | $1,499,000 |
| Depreciation And Amortization | $1,644,000 | $1,900,000 | $1,847,000 | $1,499,000 |
| Gain Loss On Sale Of PPE | $3,000 | $3,000 | $1,000 | $19,000 |
| Net Income From Continuing Operations | $-58,241,000 | $-76,404,000 | $-88,222,000 | $-75,800,000 |
| Other Non Cash Items | - | $157,000 | $223,000 | $173,000 |
| Issuance Of Debt | - | - | $0 | $975,000 |
| Long Term Debt Issuance | - | - | $0 | $975,000 |
| Gain Loss On Investment Securities | - | - | - | $203,000 |